Intercept Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Intercept Pharmaceuticals, Inc. of its common stock for up to an aggregate amount of $100 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “ICPT.”
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases with high unmet medical need utilizing its proprietary bile acid chemistry, including for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
The Davis Polk corporate team included partner Michael Kaplan, counsel Jeffrey S. Ramsay and associate Joyce Kim. Partner David R. Bauer and associate Annie Xie provided intellectual property advice. Partner Patrick E. Sigmon and associates Charles Collier and Ted Lee provided tax advice. All members of the Davis Polk team are based in the New York office.